Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis

详细信息    查看全文

• 作者：Alessandro Granito ; MD^a ; Prof Luigi Bolondi ; MD^a ; ^{luigi.bolondi@unibo.it}
• 刊名：The Lancet Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：18
• 期：2
• 页码：e101-e112
• 全文大小：115 K
• 卷排序：18

文摘

Underlying liver cirrhosis is present in most patients with hepatocellular carcinoma, and liver transplantation is the only treatment strategy to cure both diseases. All other hepatocellular carcinoma treatment strategies have to take into account residual liver function that concurs with the patient's prognosis and might limit their feasibility. In patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B (CPT-B), owing to borderline liver function, any intervention might be offset by liver function deterioration. In this setting, the decision for hepatocellular carcinoma treatment requires a comprehensive assessment of liver function, not restricted to the CPT classification, in addition to a careful evaluation of the prognostic effect of hepatocellular carcinoma compared with cirrhosis. In this Review, we provide an overview of the literature regarding the benefits and harms of non-transplant therapies in patients with hepatocellular carcinoma and CPT-B cirrhosis.